Strides Pharma Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
- June 11, 2026
- Posted by: Kunal Singla
- Category: News
Strides Pharma CMP: Rs 1,001 (2026). 52W High: Rs 1,231. 52W Low: Rs 769. Mkt Cap: Rs 9,221 Cr. P/E: 50.2. Analyst Consensus: Rs 1100. The Strides Pharma stock prediction for 2026 reflects the analyst community’s assessment of Strides Pharma Science’s competitive position, earnings trajectory and macro environment.
The Strides Pharma stock prediction for 2026 from leading brokerages covers a range reflecting sector dynamics, earnings trajectory and the macro environment. All estimates may or may not be achieved. Treat any Strides Pharma share price prediction as one data point and not as a guarantee of future performance.
This article reviews every dimension of the Strides Pharma stock forecast analysts are tracking, including key drivers, bull and bear scenarios and the primary risks. Verify all figures with the latest brokerage reports before any investment decision.
Click Here – Get Free Investment Predictions
What Analysts Predict for Strides Pharma Stock in 2026
Analyst consensus on the Strides Pharma stock prediction for 2026 is tracked by leading brokerages. The table below shows the latest available data from JM Financial and Kotak Securities. All figures are sourced from publicly available research and should be verified before publishing.
| Brokerage | Rating | Strides Pharma Stock Prediction (Rs) | Updated |
|---|---|---|---|
| JM Financial | Neutral | Rs 1150 | 2026 |
| Kotak Securities | Neutral | Rs 1050 | 2026 |
| Analyst Consensus | — | Rs 1100 | 2026 |
The Strides Pharma stock prediction range reflects genuine difference of opinion on demand recovery, margin trajectory and sector headwinds. The implied upside in the Strides Pharma stock forecast from the current price of Rs 1,001 may or may not be realised by end of 2026.
3 Stocks Building Serious Momentum Right Now
When Univest analysts identify high-conviction stock opportunities, investors pay attention.
Our research team has shortlisted the Top Stocks to Buy based on current market momentum, sector trends & growth potential for 2026.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks now on Univest
Strides Pharma Company Overview
Strides Pharma Science is a significant player in India’s pharmaceutical industry with a presence across domestic formulations, US generics and specialty segments. The Strides Pharma stock prediction for 2026 reflects both the pipeline growth potential and regulatory risk.
| Metric | Value |
|---|---|
| NSE Ticker | STAR |
| Sector | Pharmaceuticals and Healthcare |
| CMP | Rs 1,001 (2026) |
| 52 Week High | Rs 1,231 |
| 52 Week Low | Rs 769 |
| Market Cap | Rs 9,221 Cr |
| P/E Ratio | 50.2 |
| Strides Pharma Stock Prediction Consensus (12M) | Rs 1100 |
Strides Pharma Stock Prediction by Time Horizon
Analysts split the Strides Pharma share price prediction across time frames as near-term drivers differ materially from the long-term view.
Short-Term Strides Pharma Stock Prediction
The near-term Strides Pharma stock forecast reflects current sentiment, sector news and upcoming earnings prints. Key support and resistance levels around Rs 1,001 are being watched closely. A short-term Strides Pharma share price prediction carries the most uncertainty of any time horizon.
12-Month Strides Pharma Stock Prediction
JM Financial targets Rs 1150 (Neutral) and Kotak Securities targets Rs 1050 (Neutral). Most desks refresh their Strides Pharma stock forecast within two to four weeks of each quarterly earnings print. The Strides Pharma share price prediction should be verified against the most recent analyst reports.
Long-Term Strides Pharma Stock Prediction
The long-term Strides Pharma stock prediction is built on assumptions about demand recovery, margin expansion and revenue diversification in the Pharmaceuticals and Healthcare sector. The long-term Strides Pharma share price prediction carries the most uncertainty and should be treated as directional guidance only.
Strides Pharma Stock Forecast: Key Factors
The following four factors appear consistently in research reports on the Strides Pharma stock prediction and are the primary inputs into the bull and bear case scenarios.
US Generic Revenue
US generics revenue is the most watched metric in the Strides Pharma stock forecast. USFDA approval timelines and price erosion rates directly affect the Strides Pharma share price prediction from most research desks.
Domestic Formulations Growth
Domestic formulation growth provides a stable base that supports the Strides Pharma stock prediction even when export growth faces headwinds.
R&D Pipeline
The depth and commercialization pace of the R&D pipeline is a key variable in the long-term Strides Pharma share price prediction. New product approvals are cited as catalysts for the Strides Pharma stock prediction.
EBITDA Margin
Sustained EBITDA margin expansion is typically the basis for the bullish Strides Pharma stock forecast. Margin recovery strengthens the Strides Pharma share price prediction from most research desks.
Strides Pharma Stock Prediction: Bull and Bear Scenarios
| Scenario | Strides Pharma Stock Prediction | Key Conditions |
|---|---|---|
| Bull Case | Rs 1150 | Strong execution, margin improvement, favourable macro and sector re-rating |
| Base Case | Rs 1100 | Steady performance, gradual recovery, margins hold, growth on track |
| Bear Case | Rs 769 | Demand deterioration, margin pressure, sector de-rating and macro headwinds |
The bull case Strides Pharma stock forecast of Rs 1150 assumes most positive variables converge. The base case of Rs 1100 is the analyst consensus and may or may not be achieved.
How Analysts Are Reading the Strides Pharma Stock Story
Analyst reviews of the Strides Pharma share price prediction highlight the company’s core strengths in Pharmaceuticals and Healthcare alongside near-term headwinds from macro uncertainty, competitive pressure and sector-level challenges. Overall the Strides Pharma stock prediction consensus is built on real business strengths set against real risks.
Key Risks to the Strides Pharma Stock Prediction
USFDA Regulatory Risk
Import alerts and warning letters from the USFDA are the most significant risks to the Strides Pharma stock prediction. A facility closure would force an immediate sharp revision to the Strides Pharma share price prediction.
Price Erosion in the US
Pricing pressure in US generics compresses the revenue per product and affects the Strides Pharma stock forecast. Aggressive price erosion pushes the Strides Pharma share price prediction toward the bear case.
R&D Execution Risk
Delays in clinical trials or approval failures affect the Strides Pharma stock prediction. The Strides Pharma share price prediction is particularly sensitive to key pipeline asset announcements.
Currency Risk
A strengthening rupee against the dollar reduces export realisation and affects the Strides Pharma stock forecast. Currency risk is embedded in conservative Strides Pharma share price prediction models.
How to Monitor the Strides Pharma Stock Forecast
Track the Strides Pharma share price prediction consensus quarterly. After every earnings release, most brokerages revise their Strides Pharma stock forecast within two weeks. Comparing the revised Strides Pharma stock prediction to the previous estimate tells you whether analyst sentiment is improving or deteriorating.
Compare the current price of Rs 1,001 with the analyst target range of Rs 1150 to Rs 1050. A wide Strides Pharma stock prediction band reflects genuine uncertainty, so position size should reflect that range rather than the midpoint alone.
Review the Strides Pharma share price prediction every quarter against key business metrics for the Pharmaceuticals and Healthcare sector. A single estimate from any analyst is a point-in-time view and should be treated as one input among many when making any investment decision.
Check Live Strides Pharma Fundamentals on the Univest Screener
Conclusion
The Strides Pharma stock prediction for 2026 reflects the analyst community’s assessment of Strides Pharma Science’s competitive position, earnings trajectory and macro environment. JM Financial holds a Neutral stance with a target of Rs 1150 while Kotak Securities has a Neutral rating with a target of Rs 1050, giving an analyst consensus of Rs 1100.
The Strides Pharma stock forecast is set against near-term risks that make the Strides Pharma share price prediction range wide. Investors should verify any estimate with the latest brokerage reports before using it as an investment reference. The analyst forecast will be revised after every quarterly result, so tracking changes in the Strides Pharma stock prediction over time is more valuable than relying on any single estimate.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.
Download the Univest iOS App or Univest Android App to track the live Strides Pharma stock prediction and share price prediction changes in real time.
Disclaimer: Data and figures in this article are sourced from publicly available information and may or may not be accurate. Analyst price targets are from public brokerage reports and should be independently verified. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Strides Pharma Stock Prediction 2026
What is the Strides Pharma stock prediction for 2026?
Ans. The Strides Pharma stock prediction for 2026 is based on analyst consensus from JM Financial and Kotak Securities. The consensus target is Rs 1100. All estimates may or may not be achieved.
Is the Strides Pharma stock prediction bullish or bearish?
Ans. JM Financial has a Neutral rating with target Rs 1150. Kotak Securities has a Neutral rating with target Rs 1050. The Strides Pharma stock forecast reflects genuine analyst diversity of opinion.
What is the Strides Pharma share price prediction based on fundamentals?
Ans. The Strides Pharma share price prediction rests on the US generic pipeline, domestic growth, EBITDA margin and regulatory compliance track record. Analysts tracking Strides Pharma closely cite these as the primary drivers of the 2026 outlook.
What is the long-term Strides Pharma stock prediction?
Ans. The long-term Strides Pharma stock prediction assumes the company sustains its core business drivers over a multi-year horizon. The 12-month consensus of Rs 1100 is the nearest reliable anchor point.
What are the key risks to the Strides Pharma stock prediction?
Ans. The primary risks include sector-specific headwinds, macro uncertainty, regulatory changes and competitive pressure. Every Strides Pharma stock prediction should be read alongside its risk assumptions.
What does the Strides Pharma stock forecast say for 2026?
Ans. JM Financial: Neutral target Rs 1150. Kotak Securities: Neutral target Rs 1050. These Strides Pharma share price prediction estimates may or may not prove accurate.
Where can I track the latest Strides Pharma stock prediction?
Ans. Track the latest Strides Pharma stock prediction on the NSE and BSE websites and on the Univest app and screener for live price and updated analyst targets.
